Does TRICARE Cover Vyleesi (Bremelanotide)?

What Is Vyleesi and Why Does It Matter for TRICARE Beneficiaries?

Vyleesi (bremelanotide) is the only FDA-approved melanocortin receptor agonist for HSDD. It received FDA clearance in June 2019 as a self-administered, on-demand subcutaneous injection given at least 45 minutes before anticipated sexual activity. For the roughly 10 percent of premenopausal women who meet HSDD criteria, it represents one of only two approved pharmacologic options, the other being flibanserin (Addyi). TRICARE covers approximately 9.6 million beneficiaries as of the Defense Health Agency's 2023 enrollment report, and a meaningful share are women of reproductive age for whom HSDD is clinically relevant.

The RECONNECT Trial: What the Evidence Shows

The key RECONNECT program consisted of two Phase 3 randomized controlled trials (N=1,267 total) published in Obstetrics and Gynecology in 2019 [1]. Women receiving bremelanotide 1.75 mg reported a statistically significant improvement in the Female Sexual Function Index desire domain score versus placebo (mean difference 0.4 points, P<0.001) and a clinically meaningful reduction in distress measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm [1]. Nausea occurred in 40 percent of active-drug participants versus 1.3 percent on placebo, which is a key tolerability point prescribers must discuss with patients before initiating therapy.

FDA Label and Approved Population

The FDA label restricts bremelanotide to premenopausal women with generalized, acquired HSDD not attributable to a co-existing medical or psychiatric condition, relationship problems, or medication effects [2]. Prescribers submitting a TRICARE prior authorization must align their documentation precisely with this labeled population, any ambiguity about etiology will trigger a denial. The label also notes that blood pressure transiently increases after each dose (mean peak increase of approximately 2 mmHg), which can matter for patients on antihypertensives [2].

TRICARE Formulary Status for Vyleesi

Vyleesi sits outside the TRICARE Basic Core Formulary. That single fact drives every downstream coverage challenge a beneficiary faces.

Formulary Tiers Under TRICARE Pharmacy Benefits

TRICARE pharmacy benefits are administered by Express Scripts under the TRICARE Pharmacy Program contract. The program uses three primary cost-sharing tiers: Tier 1 (generic), Tier 2 (formulary brand), and Tier 3 (non-formulary brand) [3]. Vyleesi falls into Tier 3 non-formulary, meaning it requires a prior authorization before any cost-sharing applies. Without an approved PA, TRICARE will not pay any portion of the drug cost, the beneficiary bears the full $1,200 monthly list price.

Cost-Sharing Once PA Is Approved

If a prior authorization is granted, Tier 3 cost-sharing under TRICARE Prime is 20 percent of the allowed cost after the applicable catastrophic cap ($1,000 per year for active-duty family members, $3,500 for most retirees and their families) [3]. Under TRICARE Select, Tier 3 specialty drugs carry a 25 to 35 percent cost-share depending on sponsor status. Actual out-of-pocket amounts therefore vary substantially by plan and beneficiary category.

Prior Authorization Criteria for Vyleesi on TRICARE

A prior authorization for Vyleesi on TRICARE is moderate in difficulty, which means approvals do happen, but only when the clinical file is complete and specific.

Required Documentation

Prescribers should submit all of the following with the PA request to Express Scripts:

• A confirmed diagnosis of HSDD using DSM-5 criteria (ICD-10 code F52.0 or F52.10) [4]
• Documentation that the condition is generalized (not situational) and acquired (not lifelong)
• Evidence that the disorder causes marked personal distress, typically a Female Sexual Distress Scale score of 11 or higher [1]
• Ruling out of contributing medical causes: thyroid function tests, hormonal panel (FSH, LH, estradiol, testosterone, prolactin), and psychiatric screening notes
• Records of at least one prior therapeutic trial, usually flibanserin (Addyi) for a minimum of 8 weeks at the approved dose of 100 mg nightly [5]
• Attestation that the prescriber is an OB-GYN, urologist, or other specialist with relevant experience, or documentation of specialist referral

The PA form is submitted through the Express Scripts provider portal or by fax to the TRICARE Specialty Drug PA unit. Incomplete submissions are the primary reason first-submission denials occur.

Step Therapy: The Flibanserin Requirement

TRICARE generally requires a documented trial of flibanserin before approving bremelanotide. Flibanserin (Addyi) received FDA approval in August 2015 for HSDD in premenopausal women and carries a Tier 2 formulary status under TRICARE, making it the preferred first-line agent from a payer perspective [5]. The minimum required trial duration is typically 8 weeks; prescribers should note the start and stop dates, reason for discontinuation (most commonly persistent dizziness, somnolence, or inadequate response), and any dose modifications made during the trial.

A patient who cannot tolerate flibanserin due to a documented contraindication, such as concurrent moderate or strong CYP3A4 inhibitor use, hepatic impairment, or alcohol use that cannot be eliminated, may qualify for a step-therapy exception. The FDA's Risk Evaluation and Mitigation Strategy (REMS) program for flibanserin documents these contraindications, and including the REMS prescriber attestation in the PA packet strengthens the exception request [5].

Timeline and Tracking

Standard TRICARE PA reviews for specialty drugs take 7 to 14 business days. An urgent or expedited review (72-hour turnaround) applies when a treating physician certifies that delay would seriously jeopardize health, a high bar for HSDD, though it may apply in documented cases of severe distress or relationship crisis. Prescribers can check PA status through the Express Scripts provider portal or by calling the TRICARE Pharmacy Program line.

How to Appeal a TRICARE Denial of Vyleesi

A denial is not final. TRICARE's appeal process has three distinct levels, and success rates improve at each level when documentation is added.

Level 1: Reconsideration Request

Submit a reconsideration request to the Express Scripts TRICARE PA unit within 90 days of the denial notice. Include any missing documentation identified in the denial explanation, peer-reviewed literature supporting medical necessity (the RECONNECT publication is appropriate here [1]), and a signed letter of medical necessity from the prescribing physician. The reconsideration is reviewed by a pharmacist or physician advisor, not the original reviewer.

Level 2: Formal Appeal to the TRICARE Regional Contractor

If reconsideration is denied, the beneficiary (or their authorized representative) may file a formal appeal with the TRICARE regional contractor: Humana Military for the East region, or TriWest Healthcare Alliance for the West region. Submit within 90 days of the reconsideration denial. The formal appeal is reviewed by a physician independent of the contractor. Per the Defense Health Agency's Beneficiary Counseling and Assistance Coordinator (BCAC) program, beneficiaries can request BCAC support free of charge to prepare this submission [6].

Level 3: Defense Health Agency Review and Hearing

The third level involves a formal hearing or written review by the Defense Health Agency. This step is time-intensive, resolution may take 60 to 90 days, but it produces a legally binding determination. The DHA ombudsman office and the Patient Advocate General's office at the relevant military installation can assist at this stage [6].

What Strengthens an Appeal

Successful appeal packets for Vyleesi denials typically include:

• A detailed clinical narrative from the treating physician explaining why bremelanotide is medically necessary for this specific patient
• Completed Female Sexual Distress Scale-Desire/Arousal/Orgasm scores from at least two time points
• Documentation of at least one failed or contraindicated alternative (flibanserin trial records)
• Peer-reviewed evidence, particularly RECONNECT trial data [1] and the American College of Obstetricians and Gynecologists' position on female sexual dysfunction [7]
• A statement from a mental health provider if psychological distress is a component

ACOG's Committee Opinion 213 states: "Female sexual dysfunction is prevalent, affects quality of life, and can be effectively treated when correctly diagnosed and managed with patient-centered care." [7] Including this language in an appeal letter contextualizes HSDD as a legitimate medical condition requiring pharmacologic treatment.

Savings Cards and Cost Alternatives: What TRICARE Patients Can and Cannot Use

Federal law prohibits using manufacturer copay assistance cards with any federally funded insurance, including TRICARE. This restriction comes from the federal Anti-Kickback Statute and is not waivable [8]. A beneficiary who uses a manufacturer card while enrolled in TRICARE risks disenrollment or recoupment actions.

Legal Alternatives to Offset Cost

Patients who are denied coverage or cannot afford Tier 3 cost-sharing have several options:

• TRICARE Supplemental Insurance (TRICARE Supplement): Privately purchased supplemental plans sold by organizations such as AUSA and MOAA sometimes cover non-formulary drugs that TRICARE denies. Coverage varies by plan.
• Patient Assistance Programs: AMAG Pharmaceuticals (the original developer; the drug is now commercialized through Palatin Technologies' licensee) offered a patient assistance program for uninsured or underinsured patients. Check NeedyMeds.org for current program availability, as program terms change.
• Goodrx and Cash-Pay Pharmacies: Without insurance, the cash-pay price for Vyleesi ranges from approximately $1,100 to $1,300 per month. Some specialty pharmacies quote slightly lower prices with discount codes, but verify that using a discount card does not create a billing conflict with TRICARE, as billing both is prohibited [8].
• Compounded bremelanotide: Some 503A compounding pharmacies prepare bremelanotide peptide at substantially lower cost. The FDA has not approved compounded bremelanotide, and its safety and potency are not independently verified [2]. TRICARE will not cover compounded versions.

Clinical Considerations Before Prescribing Vyleesi to TRICARE Patients

Prescribers can reduce prior authorization friction by building the clinical file correctly from the first visit.

Documenting the HSDD Diagnosis Rigorously

Use DSM-5 Criterion A explicitly in the chart note: the patient must demonstrate persistently or recurrently deficient sexual desire causing marked distress or interpersonal difficulty, not better explained by another diagnosis [4]. The International Society for the Study of Women's Sexual Health (ISSWSH) Process of Care for the Management of HSDD recommends validated questionnaire scores at baseline, the Female Sexual Function Index and the Female Sexual Distress Scale-Desire/Arousal/Orgasm are the two most commonly accepted instruments [9].

The ISSWSH 2017 consensus document states: "A validated patient-reported outcome instrument should be used to establish baseline severity and track treatment response, and a score of 11 or above on the FSDS-R total scale identifies clinically relevant distress." [9]

Monitoring Cardiovascular Parameters

Bremelanotide transiently raises blood pressure. In the RECONNECT trials, systolic blood pressure increased a mean of 1.4 mmHg and diastolic 1.7 mmHg, with the peak effect at approximately 4 hours post-dose [1]. For TRICARE patients who are active-duty or veteran with pre-existing hypertension, this requires baseline blood pressure documentation and a note confirming the risk-benefit discussion. TRICARE reviewers may flag uncontrolled hypertension as a contraindication to approving the PA.

Timing Flibanserin Trial Strategically

If a prescriber anticipates that a patient will ultimately need bremelanotide, initiating a documented flibanserin trial at the first visit, rather than waiting until after a Vyleesi PA is denied, saves 8 to 12 weeks in the approval timeline. Chart the start date, dose (100 mg nightly), tolerability assessments at 4 and 8 weeks, and reason for discontinuation. This record becomes the step-therapy documentation for the Vyleesi PA.

How Vyleesi Compares to Flibanserin Under TRICARE Coverage

Both drugs are FDA-approved for HSDD in premenopausal women, but they work through different mechanisms and carry different TRICARE formulary status.

| Feature | Flibanserin (Addyi) | Bremelanotide (Vyleesi) | |---|---|---| | Mechanism | 5-HT1A agonist / 5-HT2A antagonist | Melanocortin receptor agonist (MC1R, MC4R) | | Dosing | 100 mg orally, nightly | 1.75 mg SC, on-demand (max 1x/24h) | | TRICARE tier | Tier 2 (formulary brand) | Tier 3 (non-formulary; PA required) | | Key adverse effect | Dizziness, somnolence, hypotension with alcohol | Nausea (40%), flushing, transient BP increase | | REMS program | Yes (alcohol interaction warning) | No | | Onset of effect | Weeks of daily use | 45 minutes per dose | | FDA approval year | 2015 [5] | 2019 [2] |

Flibanserin's Tier 2 status makes it substantially cheaper for TRICARE beneficiaries who respond to it. The step-therapy requirement reflects this cost hierarchy. Bremelanotide's on-demand dosing is a genuine clinical advantage for women who prefer not to take a daily medication or who have contraindications to flibanserin, and that clinical distinction is precisely what a PA letter should articulate.

Special Populations Within TRICARE

Active-Duty Servicewomen

Active-duty servicewomen receive pharmacy benefits at no cost through military treatment facilities (MTFs) and the TRICARE Mail Order Pharmacy (TMOP). Non-formulary drugs still require PA even for active-duty members. Servicewomen may face additional clinical review because of occupational health implications of drugs that cause transient blood pressure changes or nausea during duty hours. The prescribing clinician should address duty-status compatibility in the PA letter.

Tricare for Life (TFL) Beneficiaries

TFL serves Medicare-eligible military retirees and their dependents. Because TFL is secondary to Medicare, HSDD drug coverage would first route through Medicare Part D. Medicare Part D does not currently cover drugs indicated exclusively for sexual dysfunction under the Social Security Act's statutory exclusion [10]. This means TFL beneficiaries, who are postmenopausal in most cases and outside the labeled population anyway, face a dual coverage gap. Premenopausal retiree family members under age 65 using standard TRICARE Select or TRICARE Prime are unaffected by this exclusion.

Reserve Component and Guard Members

TRICARE Reserve Select and TRICARE Retired Reserve follow the same formulary and PA framework as TRICARE Prime and Select. The Express Scripts specialty drug PA unit handles submissions identically regardless of sponsor component.

Working With Your Prescriber to Maximize Approval Odds

A well-prepared PA submission takes approximately 20 to 30 minutes of prescriber time but can prevent 4 to 6 weeks of appeal delays.

The checklist a prescriber should complete before submitting:

1. Confirm DSM-5 HSDD criteria are explicitly documented in the chart note from the current visit, not just inferred from prior notes.
2. Include FSDS-DAO score of 11 or higher, or document why formal scoring was not feasible and describe equivalent distress evidence.
3. Attach flibanserin trial documentation with start date, stop date, doses, and reason for discontinuation, or attach documentation of a specific contraindication to flibanserin with reference to the REMS prescribing criteria [5].
4. Complete the standard Express Scripts TRICARE specialty PA form (available on the Express Scripts provider portal) in full, blank fields trigger automatic pend requests and add 5 to 7 business days.
5. Include the prescriber's DEA number and NPI, the patient's TRICARE sponsor Social Security Number or DoD Benefits Number, and the specific NDC code for Vyleesi 1.75 mg/0.3 mL auto-injector.

The National Academies of Sciences, Engineering, and Medicine's 2020 report on sexual health found that "clinicians consistently underutilize validated outcome measures in diagnosing and tracking treatment of female sexual dysfunction," a gap that directly contributes to PA denials that could be prevented with routine clinical assessment [11].